1st Quarter - Report

VAN HEUVELEN STRATEGIES, LLC for ALLERGAN PLC (FORMERLY KNOWN AS ACTAVIS)

Period 1st Quarter 2017 Filed Apr 20, 2017 Signed by Robert Van Heuvelen

Official filing
Firm
VAN HEUVELEN STRATEGIES, LLC
Client
ALLERGAN PLC (FORMERLY KNOWN AS ACTAVIS)
Income
$40,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to the CMS Part B Drugs Payment Model Demo Issues related to Zika funding Issues related to counterfeit drugs S. 297 - Increasing Competition in Pharmaceuticals Act H.R. 749 -Lower Drug Costs through Competition Act

LobbyistCovered position, as disclosed
ROBERT VAN HEUVELEN Chief of Staff to Senator Kent Conrad
STEPHEN DOUGLAS WARD Chief of Staff to Senator Jeff Bingaman

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 749 (115th), S. 297 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.